News
Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...
Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...
Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company ...
14h
Zacks Investment Research on MSNInvestors Heavily Search Abbott Laboratories (ABT): Here is What You Need to KnowAbbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
This week, the Senate Committee on State Affairs met to hash out the details of Senate Bill 5, which would ban THC products ...
Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...
Explore more
Abbott Laboratories stock falls after earnings even as the company reports second-quarter sales that top expectations.
Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, ...
Q2 2025 Results Conference Call July 17, 2025 9:00 AM ETCompany ParticipantsMichael Comilla - Vice President of ...
Abbott Laboratories closed 14.67% below its 52-week high of $141.23, which the company achieved on March 4th.
Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.
The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results